Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fenticonazole Nitrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Fenticonazole Nitrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Product Name : Rivalif
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 31, 2022
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Secnidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.
Product Name : Solosec
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 27, 2022
Lead Product(s) : Secnidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.
Product Name : Rizaport
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 27, 2020
Lead Product(s) : Rizatriptan Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : IntelGenx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Mexiletine
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla®
Details : Under the agreements, Exeltis Healthcare will commercialize NaMuscla® in Spain and Portugal, Cresco Pharma B.V will commercialize NaMuscla® in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMus...
Product Name : NaMuscla
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 06, 2020
Lead Product(s) : Mexiletine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : INM004
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Recipient : Exeltis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 18, 2019
Lead Product(s) : INM004
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Exeltis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tioconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Efficacy and Safety of Gynomax® XL Ovule
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2019
Lead Product(s) : Tioconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 14-C Benznidazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Insud Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Benznidazole Absorption, Metabolism and Excretion Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
November 14, 2018
Lead Product(s) : 14-C Benznidazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Insud Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable